Organization Profile

You just read:

Two-Year Update of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses with BAVENCIO® (avelumab)

News provided by

Merck KGaA

Jun 04, 2018, 09:50 ET